7 results
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
9 May 24
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
8:30am
the importance and proprietary nature of the innovation that makes this next generation anthracycline possible and bolsters our confidence in its potential
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
27 Mar 24
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
9:05am
of this patent underscores the importance and proprietary nature of the innovation that makes this next generation anthracycline possible.”
Annamycin
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
14 Apr 21
Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma
7:35am
as part of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, is intended to incentivize the development of new therapies
8-K
EX-99.1
MBRX
Moleculin Biotech Inc
13 Aug 18
Results of Operations and Financial Condition
7:24am
announced that its CEO, Walter Klemp, was asked to address the 2018 BioForum Conference in Łódź, Poland regarding the Polish-American Innovation Bridge
- Prev
- 1
- Next